Name | 7-tert-butyl-6-[(2-ethyl-1,2,4-triazol-3-yl)methoxy]-3-(2-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine |
---|---|
Synonyms |
unii-1fi3ktc550
mk0777 tpa-023 gtpl4327 TPA 023 |
Description | TPA 023 is a GABAA α2/α3 subtype-selective agonist, with Ki of 0.19-0.41 nM. |
---|---|
Related Catalog | |
Target |
Ki: 0.19-0.41 nM (GABAA)[1] |
In Vivo | TPA023 displays good receptor occupancy, when administered orally to rats. The dose of TPA023 resulting in 50% occupancy of rat brain GABAA receptors is 0.42 mg/kg, with the corresponding plasma concentration being 25 ng/mL. TPA023 is also efficacious in the mouse pentylenetetrazole-induced seizure model, providing full seizure protection at a dose of 10 mg/kg i.p. (84% occupancy), with the ED50 of 0.19-0.41 nM, for protection against tonic convulsions (1.4 mg/kg i.p.) corresponding to around 50% occupancy. TPA023 (3 mg/kg p.o. in 0.5% methyl cellulose) shows anxiolytic-like effect on rats[1]. TPA023 (0.7, 2.0, and 5 mg/kg, p.o.) blocks ketamine's cognitive-impairing ability but does not influence the behavioral symptoms of rhesus monkeys[2]. |
References |
Molecular Formula | C20H22FN7O |
---|---|
Molecular Weight | 395.43300 |
Exact Mass | 395.18700 |
PSA | 83.02000 |
LogP | 3.41830 |
Storage condition | 2-8℃ |